Indoco Remedies Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.0K Cr
Overall sales are expected to achieve a 12% to 15% CAGR over the next few years due to investments in product basket and customer growth. Expect a 12%-15% sales CAGR over the next few years driven by investments in product basket and customer growth. - Operating margins are anticipated to consistently improve quarter-on-quarter, supported by better plant efficiencies and cost controls. - India and emerging market businesses are highly profitable and expected to contribute steadily to operating profit growth. - European business profitability is set to improve as manufacturing efficiencies and product mix optimize. - U.S.
From Indoco Remedies's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹219
Market Cap
₹2.0K Cr
Revenue Rank
Margin Rank
How does Indoco Remedies rank in Pharmaceuticals & Biotechnology?
Compare Indoco Remedies against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Indoco Remedies — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net profit ₹-24 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Overall sales are expected to achieve a 12% to 15% CAGR over the next few years due to investments in product basket and customer growth.
- →API sales from the ORIC facility are expected to improve starting Q4 of the current year.
- →Domestic business growth is anticipated to be high single-digit to double-digit annually, driven by top 10 brands.
- →International business, especially Europe, is sizable and expected to improve profitability and growth.
- →U.S. business is in a high-growth phase with profitable gross contribution, projected to increase sales steadily.
- →Emerging markets show steady double-digit secondary growth, expected to rebound after minor disruptions.
- →Export business targets doubling in 2-3 years in line with capacity utilization improvements.
- →Product launches in oral solids planned in Europe by Q4; U.S. oral solid launches to follow later.
📈 Profitability & Margins
Rank 2- →Expect a 12%-15% sales CAGR over the next few years driven by investments in product basket and customer growth.
- →Operating margins are anticipated to consistently improve quarter-on-quarter, supported by better plant efficiencies and cost controls.
- →India and emerging market businesses are highly profitable and expected to contribute steadily to operating profit growth.
- →European business profitability is set to improve as manufacturing efficiencies and product mix optimize.
- →U.S. subsidiary is now profitable post inventory write-offs, and growth will continue, though working capital cycles pose challenges.
- →Debt reduction plans support healthier finance costs, aiding profitability.
- →Margin enhancement also supported by reduced batch size and operational efficiencies, including a 26% reduction in batches with equal or better sales.
- →Double-digit EBITDA margins are expected for the year despite current cost-of-goods pressure.
- →Overall, steady improvement in earnings and operating profit anticipated with cautious optimism on FDA plant approval.
🏗️ Capital Expenditure Plans
No- →For FY27, Indoco Remedies expects only maintenance capex, totaling less than INR 40-50 crores for the entire year.
- →There are no plans for major expansion capex this year; the focus is on trimming excessive costs and improving plant efficiency.
- →The company continues to invest in operational efficiencies like automation and optimizing batch sizes, but no large new capex projects are mentioned.
- →There may be future brand acquisitions in the India business to drive growth, but current priority is debt repayment over aggressive investments.
- →New product launches are planned—oral solids for Europe expected by Q4, and incremental launches in India and emerging markets, not capital-intensive but strategic.
- →Sterile plant utilization improvements depend on USFDA audit; no alternative capex plans disclosed if FDA delays persist.
💰 Fundraising & Capital Structure
No- →No explicit mention of any new fundraising through debt or equity in the current quarters or near future.
- →The company is focusing on repaying existing debt: aiming to repay around INR110 crores this year and another INR150 crores in the next year, totaling approximately INR260 crores over 7 to 18 months.
- →They plan to use proceeds from asset sales (e.g., land parcel) and some business divestitures partly towards debt repayment.
- →Current capex is maintenance-focused with a total forecast of not more than INR40-50 crores for FY27, implying no major new funding needs for expansion.
- →Management emphasizes prudent cash flow management post recent transactions to settle supplier dues and avoid cash flow issues.
- →Future investments may focus on brand acquisitions in India using internal accruals rather than new fundraising.
📋 Order Book & Pipeline
Yes- →As of Q1 FY27, Indoco Remedies Limited has an order book exceeding INR 250 crores for execution.
- →The order book mainly comprises exports with longstanding buyer partnerships ensuring consistent push on orders.
- →The order book duration is typically between 3 to 6 months, reflecting regular demand cycles and sustained customer relationships.
- →There is no fundamental issue with the order book; timing and shipment logistics caused temporary delays, not order shortages.
- →The company remains on track to double its export business in 2 to 3 years, including orders for new products.
- →Europe and emerging market order books are stable, with secondary demand showing steady double-digit growth.
- →Overall, the order book situation supports expected growth and margin expansion as production capacity utilization improves.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Indoco Remedies Q1 FY27 results?
Overall sales are expected to achieve a 12% to 15% CAGR over the next few years due to investments in product basket and customer growth. Expect a 12%-15% sales CAGR over the next few years driven by investments in product basket and customer growth. - Operating margins are anticipated to consistently improve quarter-on-quarter, supported by better plant efficiencies and cost controls. - India and emerging market businesses are highly profitable and expected to contribute steadily to operating profit growth. - European business profitability is set to improve as manufacturing efficiencies and product mix optimize. - U.S.
What is Indoco Remedies share price analysis?
Indoco Remedies currently shows a below-average growth signal. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indoco Remedies planning capital expenditure?
For FY27, Indoco Remedies expects only maintenance capex, totaling less than INR 40-50 crores for the entire year.
Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.